Table 2.
Number of serial blood samples and tumour tissue core needle biopsies
| IL-2, IFN- α and histamine (n=26) | IL-2, IFN-α (n=23) | Total (n=49) | ||||
|---|---|---|---|---|---|---|
| Week 0 | Week 5 | Week 0 | Week 5 | Week 0 | Week 5 | |
| Serial blood samples | ||||||
| Number blood samples for flow cytometry | 21 | 23 | 19 | 9 | 40 | 32 |
| Number differential white blood cell countsa | 24 | 24 | 22 | 21 | 46 | 45 |
| Tumour tissue core needle biopsies | ||||||
| Number of performed biopsies/number of patients | 25/22 | 23/20 | 18/16 | 10/9 | 43/38 | 33/29 |
| Number of evaluable biopsies/number of patients | 20/19 | 19/18 | 15/15 | 7/7 | 35/34 | 26/25 |
aBlood samples obtained from all patients evaluable for treatment response